

FOR THE DISTRICT OF DELAWARE

C.A. No. 23-0150-GBW

CONSENT JUDGMENT AND ORDER OF PERMANENT INJUNCTION

action as follows:

2. As used in this Consent Judgment and Order of Permanent Injunction, (i) the term “Patents-in-Suit” means U.S. Patent Nos. 8,791,122 and 9,284,280 respectively which, solely for purposes of this action, Lupin agrees are both valid and enforceable, (ii) the term “Lupin’s ANDA Product” means the product described in Abbreviated New Drug Application (“ANDA”)

No. 217991 (“Lupin’s ANDA”), namely Selexipag for Injection, 1800 mcg/vial as a generic version of Uptravi® IV as existing on the date of entry of this Consent Judgment, and as amended, supplemented, or replaced from time to time in the ordinary course of business, (iii) the term “Affiliate” shall mean any entity controlling, controlled by, or under common control with a Party, but only as long as such control continues, where “control” means: (1) the ownership of at least fifty percent (50%) of the equity or beneficial interest of such entity, or the right to vote for or appoint a majority of the board of directors or other governing body of such entity; or (2) the power to directly, or indirectly direct or cause the direction of the management and policies of such entity by any means whatsoever.

3. Unless otherwise authorized by Plaintiffs, Lupin, including any of its successors and assigns, is enjoined from making, using, selling or offering to sell in, or importing into, the United States Lupin’s ANDA Product, on its own part or through any Affiliate, officer, agent, servant, employee or attorney, or through any person in concert or coordination with Lupin or its Affiliates, until and after the expiration of the Patents-in-Suit, including any patent term extensions and/or patent term adjustments and during the period of any associated exclusivity.

4. The Parties agree that jurisdiction and venue for an action to enforce performance under this Consent Judgment and Order of Permanent Injunction, including for a preliminary injunction against the breaching conduct, exists in this District Court, and the Parties hereby waive any and all defenses based on personal jurisdiction and venue.

5. The Parties waive all right to appeal or otherwise move for relief from this Judgment and Order.

6. The Complaint and all remaining claims, counterclaims, or affirmative defenses in the above action are dismissed without prejudice and without costs, disbursements, or attorney fees to any party.

7. This Court retains jurisdiction to enforce or supervise performance under this Consent Judgment and Order of Permanent Injunction.

ASHBY & GEDDES

/s/ Andrew C. Mayo

Steven J. Balick (#2114)
Andrew C. Mayo (#5207)
500 Delaware Avenue, 8th Floor
P.O. Box 1150
Wilmington, DE 19899
(302) 654-1888
sbalick@ashbygeddes.com
amayo@ashbygeddes.com

Of Counsel:

Preston K. Ratliff II
Bruce M. Wexler
Sarah E. Spencer
Jessica Stauring
PAUL HASTINGS LLP
200 Park Avenue
New York, NY 10166
(212) 318-6000

Attorneys for Plaintiffs
Actelion Pharmaceuticals US, Inc.,
Actelion Pharmaceuticals Ltd and Nippon
Shinyaku Co., Ltd.

PHILLIPS, MCLAUGHLIN & HALL, P.A.

/s/ John C. Phillips, Jr.

John C. Phillips, Jr. (#110)
David A. Bilson (#4986)
Megan C. Haney (#5016)
1200 North Broom Street
Wilmington, DE 19806
(302) 655-4200
jcp@pmhdelaw.com
dab@pmhdelaw.com
mch@pmhdelaw.com

Of Counsel:

Kurt Mathas
Samantha Lerner
Linda Greene
WINSTON & STRAWN LLP
35 W. Wacker Drive
Chicago, IL 60601

Attorneys for Defendants
Lupin Ltd. and Lupin Pharmaceuticals, Inc.

IT IS SO ORDERED this 14th day February, 2024.


UNITED STATES DISTRICT JUDGE